As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.
17 Analysts have issued a Pharvaris NV forecast:
17 Analysts have issued a Pharvaris NV forecast:
Jun '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -193 -193 |
43%
43%
|
EBIT (Operating Income) EBIT | -193 -193 |
43%
43%
|
Net Profit | -196 -196 |
48%
48%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pharvaris NV is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans G. C. P. Schikan and Anne Lesage on September 30, 2015 and is headquartered in Leiden, Netherlands.
Head office | Netherlands |
CEO | Berndt Modig |
Employees | 114 |
Founded | 2015 |
Website | pharvaris.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.